Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques.
Why it matters
This project describes a deep learning system that reads MRI brain images and predicts early signs of Alzheimer's, with a web interface for uploading scans. No results from testing the system on patients are reported, so it is not yet evidence that it improves diagnosis or slows the disease.
-
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease without effective treatments. 1 Extracellular amyloid plaques, neurofibrillary tangles, neuroinflammation, and neuronal loss are the characteristics of AD neuropathology.
Why it matters
This work describes an engineered butyrate-producing yeast probiotic designed to deliver butyrate consistently, with the idea that it may mitigate Alzheimer's phenotypes through butyrate supplementation and probiotic effects. No clinical outcomes in patients are reported, so this remains a preclinical approach that has not yet been shown to treat or prevent Alzheimer's disease.
-
39/100
We highlight a general overview and methodology of TNS.
Why it matters
This paper describes the methodology of an ongoing study and reports only preliminary findings that adverse social exposome is related to ADRD biomarkers, neuropathology, and cognitive function. Because data collection is ongoing, no conclusions can yet be drawn about treating, curing, or preventing Alzheimer's disease.
-
39/100
Despite substantial investment in biomedical and pharmaceutical research over the past two decades, the global prevalence of Alzheimer's disease (AD) and AD-related dementias (AD/ADRD) is still rising.
Why it matters
This perspective discusses how data science and AI could help design combinations of drugs for Alzheimer's disease and related dementias. It is a discussion of a possible approach, not evidence that any combination therapy works to treat, cure, or prevent the disease.
-
Employing the random-effects IVW approach, we found that, as indicated by GrimAge, EAA was associated with an increased risk of AD (Odds Ratio [OR] = 1.025, 95% Confidence Interval [CI]: 1.006-1.044, p = 0.009).
Why it matters
This Mendelian randomization study found that epigenetic age acceleration, as measured by GrimAge, was associated with a slightly increased risk of Alzheimer's disease, but found no evidence that Alzheimer's disease causes epigenetic aging. The authors state that further research is needed to explore the underlying mechanisms, so this does not establish a way to prevent or treat the disease.
-
Juxtacortical free water fraction, determined at diffusion MRI, was higher in participants with Alzheimer disease compared with cognitively normal controls and associated with amyloid-β, tau, and neurodegeneration biomarkers, revealing two distinct spatiotemporal progression patterns with different impacts on neuroanatomic signatures and cognitive performance.
Why it matters
This study found higher juxtacortical free water fraction in participants with Alzheimer disease compared with cognitively normal controls, associated with amyloid-β, tau, and neurodegeneration biomarkers. It identified two spatiotemporal progression patterns with different impacts on brain structure and cognitive performance, but does not test any treatment or cure.
-
Alzheimer disease plasma biomarkers have emerged as minimally invasive, cost-effective tools for early diagnosis and disease monitoring yet their stability under common "real world" pre-analytical conditions remains incompletely characterized.
Why it matters
In this small pilot, pTau181 rose and pTau217 fell in frozen compared with fresh plasma samples, while Aβ40 and Aβ42 were generally stable. This is a sample-handling caution and does not address treatment, cure or prevention.
-
Alzheimer's disease (AD), the most prevalent form of dementia, is pathologically defined by amyloid-β (Aβ) plaques, neurofibrillary tangles, synaptic loss, and progressive neuronal degeneration.
Why it matters
This review describes neuroinflammation as a central and modifiable factor in Alzheimer's disease and discusses glial cells, genetic risk factors, and emerging therapeutic strategies. It suggests precise targeting of neuroinflammatory pathways as a future avenue but does not report a proven treatment.
-
BackgroundAir pollution has been almost exclusively measured by region-level ambient exposure of particulate matter (PM) from government agencies (e.g., EPA), which does not capture the potentially large within-region variation and takes no consideration of human mobility in daily life.
Why it matters
In a pilot study, 59 older participants wore a personal air quality sensor for 7 days and their exposure levels were correlated with Alzheimer's biomarkers. This is preliminary, small-scale work that generates hypotheses and does not show that reducing pollution prevents the disease.
-
RESUMO A Doença de Alzheimer (DA) é uma condição progressiva caracterizada pelo acúmulo de placas de beta-amiloide e emaranhados neurofibrilares de proteína tau, resultando em perda sináptica e morte neuronal.
Why it matters
This literature review reports that Alzheimer's treatment is moving beyond symptom-only therapies toward disease-modifying strategies. It notes that monoclonal antibody immunotherapies show potential to reduce amyloid plaques and slow cognitive decline but face challenges with adverse effects, and that metabolic and inflammatory modulation and non-drug interventions are also promising approaches.
-
These findings highlight hippocampal atrophy as a key pathway linking Aβ burden to cognitive impairment.
Why it matters
In people with mild cognitive impairment and early Alzheimer's disease, hippocampal atrophy mediated the link between amyloid-beta deposition and cognitive decline, and triglyceride levels moderated this relationship. This describes how a blood fat may influence the disease pathway rather than testing a treatment.
-
BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder frequently associated with dysphagia, leading to malnutrition, dehydration, and aspiration pneumonia.
Why it matters
In this study of 30 patients with Alzheimer's disease, the Eating Assessment Tool-10 detected unsafe swallowing and aspiration with different cut-off scores across disease stages, though its reliability in advanced disease where self-reporting is difficult remains uncertain. It is about screening for swallowing problems in people who already have Alzheimer's disease, not about treating, curing or preventing the disease.
-
The brain contains approximately 100 billion neurons and over 200 billion glial cells, which are integral to the neuronal networks that support normal brain function in the central nervous system.
Why it matters
This review discusses how unhealthy diets high in saturated fats and refined sugars increase neuroinflammation and oxidative stress and notes that attention has shifted to modifiable risk factors to delay Alzheimer's onset. It does not show that any dietary change prevents or treats the disease.
-
While the β-secretase BACE1 is responsible for the rate-limiting initial step to generate amyloid-β (Aβ) peptides, BACE1 inhibitor clinical trials have been halted due to a lack of efficacy and/or safety concerns at symptomatic/prodromal stages of Alzheimer's disease (AD).
Why it matters
This review reports that BACE1 levels are elevated in the cerebrospinal fluid, blood, and brains of people with mild cognitive impairment and Alzheimer's dementia, and may also be associated with asymptomatic changes in people at high risk. It notes that BACE1 inhibitor trials were halted due to lack of efficacy or safety concerns, and that many environmental and genetic risk factors converge on BACE1 elevation.
-
Utilizing machine learning, we identify a 12-protein panel from cerebrospinal fluid proteomic datasets.
Why it matters
Using machine learning on cerebrospinal fluid proteomic data, this study identified a 12-protein panel that distinguished Alzheimer's disease from mild cognitive impairment and other neurodegenerative disorders across ten cohorts and different detection technologies. It is a diagnostic biomarker study and does not report a treatment, cure or prevention.
-
Reducing risk factors is a useful way to counteract diseases.
Why it matters
This commentary discusses differences in quoted Alzheimer's disease prevalence between the US and other countries and suggests risk factor reduction and reconsidering reimbursement of amyloid PET scans. It is an opinion piece and does not report new evidence on treating, curing, or preventing the disease.
-
Alzheimer's disease (AD) is characterized by the hallmark pathologies of β-amyloid plaques and neurofibrillary tangles (NFTs), which vary across brain regions and between affected individuals.
Why it matters
Using small tissue cores with fluorescent labeling and image analysis, researchers distinguished Alzheimer's-affected brains from healthy donors and reproduced known patterns of amyloid and tau spread. This is a research method for studying postmortem brain tissue, not a treatment or diagnostic test for living patients.
-
This case report explores the therapeutic potential of lymphovenous bypass (LVB) surgery performed at the neck in neurodegenerative diseases, specifically Alzheimer's disease (AD) dementia.
Why it matters
This case report describes a single patient with severe Alzheimer's dementia who showed improved cognitive scores and reduced brain amyloid deposits after lymphovenous bypass surgery. The authors state that further research with animal experiments and clinical trials is necessary to confirm these findings.
-
Accurate classification of neurodegenerative disorders remains a challenge in neuroscience.
Why it matters
Complexity-based EEG features revealed distinct topographical differences between Alzheimer's disease and frontotemporal dementia, with AD exhibiting rostral dominance and FTD showing caudal dominance in fractal dimension. These findings suggest complexity-based EEG features may offer a reliable, cost-effective tool for distinguishing neurodegenerative conditions, complementing traditional neuroimaging.
-
During a median follow-up period of 4.6 years, stroke, MACEs, and AD dementia occurred in 24, 36, and 21 patients, respectively.
Why it matters
In patients with vascular risk factors, higher serum IL-6 was linked to a higher risk of stroke and cardiovascular events over about 4.6 years. However, no association was found between IL-6 levels and Alzheimer's disease dementia.
-
39/100
Depression in Alzheimer's disease (AD) dementia has become an increasingly recognized public health concern due to its high prevalence and substantial impact on patient outcomes.
Why it matters
This review describes shared biological pathways between depression and Alzheimer's dementia and notes that current treatments are largely nonspecific. It highlights gaps in understanding and the need for targeted, personalized approaches rather than reporting a new therapy.
-
= 62.87, SD = 9.46, 36.52% female). Both networks were densely connected, reflecting comorbidity between neuropsychiatric symptoms and cognitive scores.
Why it matters
This network analysis found that clinical symptom networks differ between Alzheimer's disease and behavioral variant frontotemporal dementia, with different bridge symptoms in each. It suggests treating bridge symptoms may relieve overall symptom burden, but this is a characterization study and does not test treatment, cure or prevention.
-
OSA components are positively associated with the risk of ADRD.
Why it matters
In this UK Biobank cohort, having more body composition abnormalities was associated with higher risk of Alzheimer's disease-related dementia, and healthy cardiovascular status appeared to weaken this association. This is an observational finding about risk factors and does not show that changing body composition or cardiovascular health prevents dementia.
-
Proliferation of microglia represents a physiological process, which is accelerated in several neurodegenerative disorders including Alzheimer disease (AD).
Why it matters
In mice with Alzheimer's-like pathology, newly divided microglia cleared beta-amyloid less effectively, and a molecule called DDX3X was identified as influencing microglial activation. This is early animal and laboratory work that points to a possible role of microglial proliferation in disease progression.
-
value = 0.04). ε4 on cognition is mediated by structural brain imaging markers, driven mainly by cerebral microbleeds.
Why it matters
This analysis found that the effect of APOE ε4 on cognition was mediated by structural brain imaging markers, mainly cerebral microbleeds, while mediation by these markers was limited for dementia. It helps explain how a known genetic risk factor relates to cognition but does not offer a treatment or cure.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Effects of the Finnish Alzheimer disease exercise trial (FINALEX): a randomized controlled trial
- Molecular mapping of Alzheimer-type dementia in Down's syndrome
- Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome
- Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population
- DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain
- Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning
- Neuroinflammation in vascular cognitive impairment and dementia: Insights from clinical biomarkers and experimental models
- Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease
- Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis
- Effects of Medicare predictors in health disparities in the risk of Alzheimer's disease